5-Amino-1MQ

Quick Facts

Introduction

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule research compound studied as an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). NNMT has become a focus of metabolic research because it sits at a junction between two important cellular currencies — the NAD+ salvage pathway and the methyl-donor (S-adenosylmethionine) pool — and 5-Amino-1MQ is one of the better-characterized membrane-permeable tools for probing what happens when that enzyme is blocked. It is frequently grouped with other non-hormonal metabolic agents such as the ERR agonist SLU-PP-332 and the mitochondrial uncoupler BAM-15.

The conceptual appeal of NNMT inhibition is that NNMT is highly expressed in adipose tissue and is associated with obesity and insulin resistance in research models. By inhibiting it, 5-Amino-1MQ is studied as a way to nudge cellular metabolism toward a more energy-burning state — a different molecular angle on the same body-composition questions explored by mitochondrial-derived peptides like MOTS-c.

This profile covers what 5-Amino-1MQ is, its molecular characteristics as a non-peptide quinolinium compound, the NNMT mechanism it engages, the metabolic research it appears in, and how it compares with related metabolic compounds. Related entries are catalogued in the peptide database.

What is 5-Amino-1MQ?

5-Amino-1MQ is a quinolinium-based small molecule, structurally related to the product of the reaction NNMT catalyzes (1-methylnicotinamide). This product-like design is the basis of its activity: it is studied as a membrane-permeable, selective inhibitor that occupies the enzyme and prevents it from methylating its natural substrate, nicotinamide.

Because it is a non-peptide, 5-Amino-1MQ has no amino-acid sequence and is handled like a classical small molecule rather than a reconstituted peptide. Its research interest comes from its enzymatic target, not from any hormonal or receptor activity of its own.

Molecular and structural characteristics

5-Amino-1MQ is a low-molecular-weight, permanently charged quinolinium cation bearing an amino substituent that contributes to its binding at the NNMT active site. Its small size and product-mimetic shape are what allow it to act as a competitive-type inhibitor while remaining membrane-permeable enough to act inside cells — a property earlier NNMT inhibitors lacked.

Because it is not a peptide, 5-Amino-1MQ does not require the aqueous reconstitution workflow used for injectable peptides catalogued in the peptide database; it is generally prepared as a salt for laboratory work.

Mechanism of action

5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) onto nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. By blocking this reaction, the compound is studied for two simultaneous consequences: it spares nicotinamide so that more is available for the NAD+ salvage pathway, and it preserves the cellular methyl-donor pool.

In adipose tissue, where NNMT is abundantly expressed, this dual effect is associated in research models with increased cellular energy expenditure and altered lipid handling. The leading mechanistic interpretation in the literature is that inhibiting NNMT shifts the balance of nicotinamide and methyl metabolism in a direction that favors a more metabolically active adipocyte phenotype.

This mechanism is distinct from — but conceptually adjacent to — other metabolic tools that raise energy turnover. The ERR agonist SLU-PP-332 reprograms transcription, the uncoupler BAM-15 dissipates the proton gradient, and 5-Amino-1MQ acts at the enzymatic level of NAD+ and methyl metabolism. Researchers study them as complementary probes of energy balance.

• Competitive-type inhibition of NNMT at its active site.
• Sparing of nicotinamide for NAD+ salvage.
• Preservation of the S-adenosylmethionine methyl-donor pool.
• Association with increased adipocyte energy expenditure in models.
• Studied for effects on lipid handling and body weight.

Metabolic and adipose research

The defining research context for 5-Amino-1MQ is adipose-tissue metabolism. Because elevated NNMT expression in white adipose tissue is associated with obesity and insulin resistance in research models, inhibiting the enzyme has been studied as a way to counter diet-induced weight gain. Preclinical reports describe associations between 5-Amino-1MQ administration and reductions in body weight and adiposity in diet-challenged rodents, without the appetite-driven mechanism characteristic of incretin compounds.

A second strand of interest concerns the NAD+ axis. NAD+ is central to mitochondrial function and to sirtuin signaling, and approaches that raise NAD+ availability are widely studied for metabolic and aging-related endpoints. By sparing nicotinamide for NAD+ salvage, 5-Amino-1MQ overlaps conceptually with that broader NAD+ research conversation and with mitochondrial agents such as MOTS-c.

Muscle and regeneration research

Beyond adipose tissue, NNMT has been studied in skeletal-muscle biology, where it influences the methyl-donor and NAD+ environment that supports muscle-stem-cell (satellite-cell) function and regenerative capacity. Some research has examined NNMT inhibition in the context of age-related decline in muscle regeneration, framing the enzyme as a metabolic brake whose removal may restore a more youthful methylation/NAD+ balance.

This regenerative framing situates 5-Amino-1MQ in a wider research landscape concerned with metabolic aging — overlapping with the interests behind mitochondrial-derived peptides like MOTS-c and Humanin. As with the metabolic work, these are early-stage, mechanism-focused observations rather than established outcomes.

Comparison: 5-Amino-1MQ vs SLU-PP-332 vs BAM-15

5-Amino-1MQ is most usefully compared with two other non-hormonal metabolic research compounds: SLU-PP-332, an ERR transcriptional agonist, and BAM-15, a mitochondrial uncoupler. All three are studied for metabolic and body-composition endpoints through distinct molecular mechanisms.

The unifying theme is increasing energy expenditure or remodeling metabolism without primarily suppressing appetite. Full entries for SLU-PP-332 and BAM-15 are available, and related compounds are catalogued in the peptide database.

Half-life and pharmacokinetic considerations

As a small, charged quinolinium molecule, 5-Amino-1MQ has pharmacokinetics distinct from peptides. Its membrane permeability is a deliberately engineered feature that allows it to reach the intracellular NNMT enzyme, and preclinical research has used repeated administration to maintain enzyme inhibition over time.

Because its biological effect depends on the degree and duration of enzyme inhibition rather than on receptor occupancy, researchers treat the relationship between plasma concentration and downstream metabolic readouts (NAD+ levels, methylation status) as indirect and time-dependent. Precise human pharmacokinetic parameters are not established.

Reconstitution and handling considerations

Unlike lyophilized peptides, 5-Amino-1MQ is a small molecule, typically supplied as a salt and dissolved in aqueous buffer or an appropriate co-solvent for stock solutions rather than reconstituted in the peptide sense. Handling emphasizes accurate weighing and protection from light and moisture.

Because the peptide reconstitution workflow does not directly apply, the reconstitution calculator and reconstitution guide are most relevant for the peptide compounds it is compared against rather than for 5-Amino-1MQ itself.

• Treat as a small molecule salt, not a reconstituted peptide.
• Dissolve in aqueous buffer or an appropriate co-solvent for stocks.
• Weigh accurately; low working masses amplify weighing error.
• Protect prepared stocks from light and excess warmth.

Storage considerations

Powdered 5-Amino-1MQ is most stable kept frozen at −20 °C, dry and away from light. Prepared stock solutions are typically refrigerated or frozen, kept dark, and protected from repeated freeze–thaw cycles; aliquoting reduces how often a given stock is cycled.

Research limitations

5-Amino-1MQ is an early-stage research compound, and its evidence base is limited largely to preclinical cell and rodent studies. NNMT participates in multiple metabolic and epigenetic processes, so the long-term and tissue-specific consequences of sustained inhibition remain open research questions. The absence of human data further constrains interpretation. It is described here strictly for research reference.

• Evidence is largely preclinical; human data are not established.
• NNMT influences both NAD+ and methylation biology — broad downstream effects.
• Long-term and tissue-specific consequences are unresolved.
• Reported effects are model-, dose-, and design-dependent.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018.
2. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014.Source
3. Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends in Endocrinology & Metabolism. 2017.